Ranpirnase - Orgenesis
Alternative Names: Amphibian ribonuclease A; Onconase; P-30 protein - Alfacell; P-30 ribonucleaseLatest Information Update: 28 Jul 2023
At a glance
- Originator Alfacell Corporation
- Developer Alfacell Corporation; Orgenesis; Tamir Biotechnology
- Class Antineoplastics; Antivirals; Eye disorder therapies; Ribonucleases
- Mechanism of Action Apoptosis stimulants; Protein synthesis inhibitors; Ribonuclease replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Genital warts
- No development reported COVID 2019 infections; Ebola virus infections; HIV infections; Zika virus infection
- Discontinued Acute myeloid leukaemia; Brain cancer; Chronic lymphocytic leukaemia; Mesothelioma; Neuroblastoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in USA (Parenteral)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA (Parenteral)
- 28 Apr 2022 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)